OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
2019
2019
Historique:
received:
27
03
2018
accepted:
21
12
2018
entrez:
1
2
2019
pubmed:
1
2
2019
medline:
1
2
2019
Statut:
epublish
Résumé
Inactivated influenza vaccines (IIVs) lack broad efficacy. Cellular immunity to a conserved internal antigen, the nucleoprotein (NP), has been correlated to protection against pandemic and seasonal influenza and thus could have the potential to broaden vaccine efficacy. We developed OVX836, a recombinant protein vaccine based on an oligomerized NP, which shows increased uptake by dendritic cells and immunogenicity compared with NP. Intramuscular immunization in mice with OVX836 induced strong NP-specific CD4+ and CD8+ T-cell systemic responses and established CD8+ tissue memory T cells in the lung parenchyma. Strikingly, OVX836 protected mice against viral challenge with three different influenza A subtypes, isolated several decades apart and induced a reduction in viral load. When co-administered with IIV, OVX836 was even more effective in reducing lung viral load.
Identifiants
pubmed: 30701093
doi: 10.1038/s41541-019-0098-4
pii: 98
pmc: PMC6344521
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4Déclaration de conflit d'intérêts
J.d.C. and F.H. are named as inventors on a family of patents/patent applications “Influenza Nucleoprotein vaccines” (WO 2014/090905, WO 2014/147087), and both are shareholders and employees of OSIVAX. The remaining authors declare no competing interests.
Références
J Immunol. 1999 Apr 1;162(7):4163-70
pubmed: 10201942
J Virol. 1999 Nov;73(11):9679-82
pubmed: 10516084
Emerg Infect Dis. 2002 Aug;8(8):796-801
pubmed: 12141964
J Immunol. 2005 Jun 1;174(11):6592-7
pubmed: 15905497
J Immunol. 2005 Jul 1;175(1):599-606
pubmed: 15972697
Vaccine. 2005 Nov 16;23(46-47):5404-10
pubmed: 16011865
J Infect Dis. 2006 Jan 1;193(1):49-53
pubmed: 16323131
Emerg Infect Dis. 2006 Jan;12(1):48-54
pubmed: 16494717
Nature. 2006 Dec 21;444(7122):1078-82
pubmed: 17151603
Vaccine. 2007 Apr 30;25(17):3263-9
pubmed: 17280748
Anal Chem. 2007 Apr 15;79(8):3164-72
pubmed: 17361989
J Immunol. 2008 Jan 1;180(1):454-63
pubmed: 18097047
Infect Immun. 2008 Aug;76(8):3817-23
pubmed: 18474650
J Virol Methods. 2008 Dec;154(1-2):121-7
pubmed: 18789973
PLoS One. 2009;4(5):e5538
pubmed: 19440239
PLoS One. 2009 Nov 12;4(11):e7790
pubmed: 19915662
BMC Infect Dis. 2010 Jun 14;10:168
pubmed: 20546586
Arch Virol. 2010 Nov;155(11):1765-75
pubmed: 20652335
MMWR Recomm Rep. 2010 Aug 6;59(RR-8):1-62
pubmed: 20689501
Biomaterials. 2010 Nov;31(32):8475-83
pubmed: 20708258
Expert Rev Vaccines. 2010 Nov;9(11):1325-41
pubmed: 21087110
Clin Infect Dis. 2011 Jan 1;52(1):1-7
pubmed: 21148512
J Immunol. 2011 Feb 1;186(3):1503-11
pubmed: 21187449
J Virol. 2011 May;85(10):5027-35
pubmed: 21367900
Proc Natl Acad Sci U S A. 2011 May 31;108(22):9178-83
pubmed: 21562214
J Biomed Biotechnol. 2011;2011:939860
pubmed: 22007149
Nat Med. 2012 Jan 29;18(2):274-80
pubmed: 22286307
Pediatr Infect Dis J. 2012 Jun;31(6):e86-91
pubmed: 22466328
PLoS One. 2012;7(3):e33555
pubmed: 22470455
PLoS One. 2012;7(9):e44943
pubmed: 22984589
Influenza Other Respir Viruses. 2013 Sep;7(5):750-8
pubmed: 22998622
J Virol. 1990 Apr;64(4):1487-97
pubmed: 2319644
Virol J. 2012 Dec 29;9:322
pubmed: 23272943
J Mol Biol. 2013 Apr 26;425(8):1302-17
pubmed: 23274142
Immunol Cell Biol. 2013 Feb;91(2):184-94
pubmed: 23399741
Sci Rep. 2013;3:1443
pubmed: 23485942
BMC Med. 2013 Jun 25;11:153
pubmed: 23800265
Nat Med. 2013 Oct;19(10):1305-12
pubmed: 24056771
Cell. 1986 Mar 28;44(6):959-68
pubmed: 2420472
Mol Ther. 2014 Mar;22(3):668-674
pubmed: 24374965
PLoS One. 2014 Feb 11;9(2):e88340
pubmed: 24523886
MMWR Morb Mortal Wkly Rep. 2015 Jan 16;64(1):10-5
pubmed: 25590680
Hum Vaccin Immunother. 2015;11(2):397-406
pubmed: 25607884
Am J Respir Crit Care Med. 2015 Jun 15;191(12):1422-31
pubmed: 25844934
Nat Commun. 2015 May 13;6:6833
pubmed: 25967273
Cell Rep. 2015 Jul 7;12(1):1-6
pubmed: 26119736
Infect Genet Evol. 2015 Aug;34:200-10
pubmed: 26140959
J Virol. 2015 Nov;89(22):11275-83
pubmed: 26311880
Sci Rep. 2015 Oct 16;5:15279
pubmed: 26472175
Sci Rep. 2016 Jan 08;6:18848
pubmed: 26743316
Hum Vaccin Immunother. 2016 Apr 2;12(4):1070-9
pubmed: 26752023
Lancet Infect Dis. 2016 Aug;16(8):942-51
pubmed: 27061888
Sci Rep. 2016 Nov 24;6:37651
pubmed: 27883012
J Struct Biol. 2017 Mar;197(3):294-307
pubmed: 28007449
Clin Microbiol Infect. 2017 Apr;23(4):222-228
pubmed: 28216325
Sci Rep. 2017 Dec 21;7(1):18000
pubmed: 29269879
J Gen Virol. 1987 Feb;68 ( Pt 2):433-40
pubmed: 3493324
J Gen Virol. 1985 Jun;66 ( Pt 6):1327-31
pubmed: 3874261
Vaccine. 1994 Jun;12(8):747-52
pubmed: 8091854
Science. 1993 Mar 19;259(5102):1745-9
pubmed: 8456302
J Virol. 1998 Jul;72(7):5648-53
pubmed: 9621023